Are drug labels static or dynamic?
Understanding drug metabolism is essential for identifying drug-drug interactions (DDIs). As new data concerning a drug's pharmacokinetics arise, updates to drug labels and administration procedures should rapidly follow. However, the US Food and Drug Administration (FDA) has inconsistently updated drug labels, based on new research findings (i.e., in peer-reviewed publications). In this Commentary, we highlight recent findings on the metabolism of imatinib and argue for a more stringent protocol for updating drug labels.